Biotech Values

[bladerunner1717]

Leerink Swann initiates coverage of CLDX with $18 price target



PRE-MKT: CLDX UP on $18 target price announcement

UPDATE: Leerink Swann Starts Celldex Therapeutics (CLDX) at Outperform
7:18 AM ET, 03/06/2013 - Street Insider
(Updated - March 6, 20137:23 AM EST)

Leerink Swann initiated coverage on Celldex Therapeutics (NASDAQ: CLDX) with an Outperform rating and a price target of $18.

Analyst Howard Liang said, "With 6 wholly owned clinical-stage biologics assets providing multiple shots on goal, the breadth of its portfolio is rare among small and mid-cap biotech companies."

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $10.71 yesterday, with a 52 week range of $3.52-$10.84.


Bladerunner